OCU410 Gene Therapy Reduces Geographic Atrophy Lesion Growth by 31% in Positive Phase 2 Data; Ocugen to Advance to Phase 3
summarizeSummary
Ocugen announced positive 12-month topline data from its Phase 2 ArMaDa clinical trial for OCU410, a modifier gene therapy for geographic atrophy (GA). The optimal dose group demonstrated a statistically significant 31% reduction in GA lesion growth compared to control (p<0.05) and a 27% slower rate of ellipsoid zone loss, alongside a clean safety profile. This announcement delivers the specific clinical results that were anticipated following yesterday's news of an upcoming webcast to discuss the OCU410 data. The strong efficacy and safety data significantly de-risks a key pipeline asset, which is crucial for Ocugen, especially given the 'going concern' warning noted in its recent 10-K. The company plans to initiate the Phase 3 registrational trial in Q3 2026, which could be a transformative step towards addressing a large unmet medical need. Investors will now focus on the Phase 3 trial design and potential financing strategies to support its development.
At the time of this announcement, OCGN was trading at $2.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $688.6M. The 52-week trading range was $0.56 to $2.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.